SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
STEM_1407_sm_SuppFigure1.tif1316KSupplemental Figure S1: Expression of putative stem cell markers on RCC-26 and RCC-53 cells. Cells were stained with fluorochrome-coupled antibodies (solid lines) and analyzed by flow cytometry. Unstained cells served as negative control (stippled lines). The fraction in % of positive cells exceeding the maximal autofluorescence of unlabeled cells is indicated..
STEM_1407_sm_SuppFigure2.tif669KSupplemental Figure S2: Inhibition of RCC-26 and RCC-53 by pazopanib, sunitinib and sorafenib. Cells were cultured in the presence of pazopanib, sunitinib and sorafenib at the indicated concentrations for 72 h. Cell viability was determined in comparison to cultures treated with the solvent alone. The IC50 values are indicated by dotted lines. The experiments were performed thrice in triplicates. Results are shown as means and SEM.
STEM_1407_sm_SuppTable1.pdf54KSupplemental Table S1: List of oligonucleotide primers and PCR products.
STEM_1407_sm_SuppTable2.pdf11KSupplemental Table S2: Correlation of CXCR4 expression in primary RCC and clinicopathologic variables.
STEM_1407_sm_SuppTable3.pdf47KSupplemental Table S3: Multivariate analyses of overall survival in patients with RCC.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.